Development of parallel reaction monitoring (PRM)-based quantitative proteomics applied to HER2-Positive breast cancer - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Oncotarget Année : 2018

Development of parallel reaction monitoring (PRM)-based quantitative proteomics applied to HER2-Positive breast cancer

Emilie Agavnian
  • Fonction : Auteur
Patrice Viens
  • Fonction : Auteur
  • PersonId : 934205

Résumé

treatments targeting the Human Epidermal Growth Factor Receptor 2 (HER2/ERBB2) have improved the natural history of HER2-positive breast cancer. However, except HER2 protein expression and gene amplification, there is no predictive biomarker to guide the HER2-targeted therapies. We developed Parallel reaction monitoring (PRM) a powerful approach, to quantify and evaluate key proteins involved in the HER2 pathway and/or anti-HER2 treatment sensitivity.
Fichier principal
Vignette du fichier
Oncotarget 2018 Guerin (1).pdf (2.06 Mo) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte
Loading...

Dates et versions

hal-02145636 , version 1 (03-06-2019)

Identifiants

Citer

Mathilde Guérin, Anthony Gonçalves, Yves Toiron, Emilie Baudelet, Matthieu Pophillat, et al.. Development of parallel reaction monitoring (PRM)-based quantitative proteomics applied to HER2-Positive breast cancer. Oncotarget, 2018, 9 (73), pp.33762-33777. ⟨10.18632/oncotarget.26031⟩. ⟨hal-02145636⟩
119 Consultations
91 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More